Impact of prostate cancer testing: an evaluation of the emotional consequences of a negative biopsy result.

Impact of prostate cancer testing: an evaluation of the emotional consequences of a negative biopsy result.

BACKGROUND: When testing for prostate cancer, as many as 75% of men with a raised prostate-specific antigen (PSA) have a benign biopsy result. Little is known about the psychological effect of this result for these men. METHODS: In all, 330 men participating in the prostate testing for cancer and tr...

Bibliografske podrobnosti
Main Authors:	Macefield, R, Metcalfe, C, Lane, J, Donovan, J, Avery, K, Blazeby, J, Down, L, Neal, D, Hamdy, F, Vedhara, K
Format:	Journal article
Jezik:	English
Izdano:	2010

Podobne knjige/članki

Predictors of attendance for prostate-specific antigen screening tests and prostate biopsy.
od: Avery, K, et al.
Izdano: (2012)

Predictors of attendance for prostate-specific antigen screening tests and prostate biopsy
od: Avery, K, et al.
Izdano: (2012)

Do the risk factors of age, family history of prostate cancer or a higher prostate specific antigen level raise anxiety at prostate biopsy?
od: Macefield, R, et al.
Izdano: (2009)

Experiences and decision processes during PSA testing and prostate biopsy: A qualitative study
od: Avery, K, et al.
Izdano: (2007)

Prostate-specific antigen testing and prostate biopsy: are self-reported lower urinary tract symptoms and health-related quality of life associated with the decision to undergo these investigations?
od: Avery, K, et al.
Izdano: (2008)

Decision-making about PSA testing and prostate biopsies: a qualitative study embedded in a primary care randomised trial.
od: Avery, K, et al.
Izdano: (2008)

Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study
od: Rosario, D, et al.
Izdano: (2012)

Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study.
od: Rosario, D, et al.
Izdano: (2012)

Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: Prospective evaluation within ProtecT study
od: Rosario, D, et al.
Izdano: (2012)

Seasonal variation in prostate-specific antigen levels: A large cross-sectional study of men in the UK
od: Down, L, et al.
Izdano: (2011)

Seasonal variation in prostate-specific antigen levels: a large cross-sectional study of men in the UK.
od: Down, L, et al.
Izdano: (2011)

Patient-reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of life.
od: Lane, A, et al.
Izdano: (2016)

Factors distinguishing general practitioners who more readily participated in a large randomized trial were identified.
od: Down, L, et al.
Izdano: (2009)

MEN WITH PROSTATE CANCER MAKE POSITIVE DIETARY CHANGES FOLLOWING TREATMENT IN A RANDOMISED TRIAL: A PROSPECTIVE COHORT STUDY
od: Avery, K, et al.
Izdano: (2012)

Latest results from the UK trials evaluating prostate cancer screening and treatment: the CAP and ProtecT studies.
od: Lane, J, et al.
Izdano: (2010)

Association of diabetes mellitus with prostate cancer: nested case-control study (Prostate testing for cancer and treatment study).
od: Turner, E, et al.
Izdano: (2011)

ProDiet: A phase II randomized placebo-controlled trial of green tea catechins and lycopene in men at increased risk of prostate cancer
od: Lane, JA, et al.
Izdano: (2018)

Longitudinal prostate-specific antigen reference ranges: Choosing the underlying model of age-related changes
od: Simpkin, A, et al.
Izdano: (2013)

ASSOCIATIONS OF SEXUAL DYSFUNCTION WITH LOCALIZED AND ADVANCED PROSTATE CANCER: A CASE-CONTROL STUDY NESTED WITHIN THE UK POPULATION-BASED PROTECT (PROSTATE TESTING FOR CANCER AND TREATMENT) STUDY
od: Collin, S, et al.
Izdano: (2009)

Detection of prostate cancer in unselected young men: prospective cohort nested within a randomised controlled trial.
od: Lane, J, et al.
Izdano: (2007)

Prostate cancer detection in men aged 45-49 years in the UK protect (prostate testing for cancer and treatment) trial
od: Hamdy, F, et al.
Izdano: (2006)

Evaluating the Prostate Cancer Prevention Trial High Grade Prostate Cancer Risk Calculator in 10 international biopsy cohorts: results from the Prostate Biopsy Collaborative Group.
od: Ankerst, D, et al.
Izdano: (2014)

The protect trial - Evaluating the effectiveness of treatments for clinically localised prostate cancer and associated molecular and genetic epidemiology studies
od: Lane, J, et al.
Izdano: (2007)

Associations of sexual dysfunction symptoms with PSA-detected localised and advanced prostate cancer: a case-control study nested within the UK population-based ProtecT (Prostate testing for cancer and Treatment) study.
od: Collin, S, et al.
Izdano: (2009)

Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group.
od: Ankerst, D, et al.
Izdano: (2012)

Ethics of clinical trials from bayesian perspective: randomisation to clinical trials may solve dilemma of treatment choice in prostate cancer.
od: Hamdy, F, et al.
Izdano: (2003)

THE PROTECT TRIAL - EVALUATING THE EFFECTIVENESS OF TREATMENTS FOR CLINICALLY LOCALISED PROSTATE CANCER
od: Lane, J, et al.
Izdano: (2009)

Contribution of a single repeat PSA test to prostate cancer risk assessment: experience from the ProtecT study.
od: Rosario, D, et al.
Izdano: (2008)

Associations of aspirin, nonsteroidal anti-inflammatory drug and paracetamol use with PSA-detected prostate cancer: findings from a large, population-based, case-control study (the ProtecT study).
od: Murad, A, et al.
Izdano: (2011)

FUSION PROSTATE BIOPSY IN PATIENTS WITH PREVIOUS NEGATIVE STANDARD PROSTATE BIOPSY
od: A. A. Keln, et al.
Izdano: (2018-01-01)

The ProtecT trial - Evaluating the effectiveness of treatment for clinically localised prostate cancer (ISRCTN20141297)
od: Lane, J, et al.
Izdano: (2004)

Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group.
od: Roobol, M, et al.
Izdano: (2012)

Screening for prostate cancer. The case against.
od: Donovan, J, et al.
Izdano: (2005)

The protecT (prostate testing for cancer and treatment) study: Evaluating screening and treatment of clinically localised prostate cancer in the UK
od: Hamdy, F, et al.
Izdano: (2006)

10-year outcomes in localized prostate cancer.
od: Hamdy, F, et al.
Izdano: (2017)

Measuring the psychosocial impact of population-based prostate-specific antigen testing for prostate cancer in the UK.
od: Brindle, L, et al.
Izdano: (2006)

Understanding factors influencing questionnaire response rates to maximise retention in a long term complex intervention trial
od: Lane Athene J, et al.
Izdano: (2011-12-01)

The protect (prostate testing for cancer and treatment) study: Advanced cases found through a UK screening study
od: Neal, D, et al.
Izdano: (2006)

10-year outcomes in localized prostate cancer: Authors' reply
od: Hamdy, F, et al.
Izdano: (2017)

The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group.
od: Vickers, A, et al.
Izdano: (2010)